As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?

Blockchain is moving toward definitive uses in clinical trials to enhance clinical supply capabilities, with the potential of enabling data ownership for patients.

As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.

A multitude of data sources leaves clinical data management systems in catch-up mode—and researchers dizzy trying to follow the data—but there is hope for simplification on the horizon.

Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

Tackling the limitations of R&D—at different stages of the journey.

Insights on the challenges, activity, and motives in merging the two areas.

Lisa Henderson examines the rise and reach of biopharma in the key Northeast Corridor clusters of Boston, Philadelphia, and New Jersey.

With increasing responsibilities and decision-making post-discovery, the traditional label of “biotech” is changing, writes Lisa Henderson.

A common thread in our exploration of "Emerging Biopharma" is that these companies need to be those that look beyond pure discovery—and put equal effort into the pivot to potential commercialization.

PharmExec talks to Dr. Gil Van Bokkelen, co-founder of Athersys, a company looking to forge new advances in the stem cell arena.

Pharm Exec convenes an expert panel to discuss new ways to navigate the many complexities of assessing business and risk in the life sciences.